Privium Fund Management B.V. Sells 61,486 Shares of uniQure N.V. $QURE

Privium Fund Management B.V. trimmed its position in uniQure N.V. (NASDAQ:QURE) by 13.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 386,000 shares of the biotechnology company’s stock after selling 61,486 shares during the quarter. uniQure makes up approximately 4.1% of Privium Fund Management B.V.’s portfolio, making the stock its 8th largest position. Privium Fund Management B.V. owned approximately 0.70% of uniQure worth $22,531,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the company. Woodline Partners LP boosted its stake in uniQure by 25.0% in the 1st quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after purchasing an additional 35,175 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in shares of uniQure in the second quarter valued at $117,000. Aberdeen Group plc boosted its position in shares of uniQure by 24.2% in the second quarter. Aberdeen Group plc now owns 2,750,714 shares of the biotechnology company’s stock worth $38,345,000 after buying an additional 535,163 shares during the period. Y Intercept Hong Kong Ltd purchased a new position in shares of uniQure during the second quarter valued at $872,000. Finally, Teacher Retirement System of Texas acquired a new position in uniQure during the second quarter valued at $151,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Insider Buying and Selling

In other news, Director Jack Kaye sold 6,390 shares of the company’s stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $27.28, for a total value of $174,319.20. Following the sale, the director directly owned 20,439 shares in the company, valued at approximately $557,575.92. This represents a 23.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Robert Gut sold 25,613 shares of the company’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $24.62, for a total value of $630,592.06. Following the completion of the sale, the director owned 32,342 shares in the company, valued at $796,260.04. This trade represents a 44.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 102,247 shares of company stock worth $2,839,298 over the last ninety days. Company insiders own 4.79% of the company’s stock.

uniQure Price Performance

NASDAQ:QURE opened at $22.72 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 7.12 and a quick ratio of 7.12. The company has a fifty day moving average price of $23.63 and a 200 day moving average price of $28.33. uniQure N.V. has a one year low of $7.76 and a one year high of $71.50. The stock has a market cap of $1.42 billion, a P/E ratio of -5.18 and a beta of 0.68.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.53). uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%. The firm had revenue of $3.70 million during the quarter, compared to analyst estimates of $4.46 million. Analysts anticipate that uniQure N.V. will post -3.75 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Chardan Capital reissued a “buy” rating and issued a $53.00 price target on shares of uniQure in a research report on Thursday, December 4th. Barclays assumed coverage on uniQure in a report on Tuesday. They set an “equal weight” rating and a $31.00 price target for the company. Benchmark reiterated a “buy” rating on shares of uniQure in a research note on Tuesday, November 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of uniQure in a research report on Wednesday, January 21st. Finally, William Blair restated a “market perform” rating on shares of uniQure in a report on Tuesday, November 11th. Ten research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $58.33.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.